Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.45 |
| ▸ | PRKG1 | Q13976 | 4/20 | 0.45 |
| ▸ | RPS6KA5 | O75582 | 3/20 | 0.45 |
| ▸ | CDK1 | P06493 | 3/20 | 0.45 |
| ▸ | PRKACA | P17612 | 3/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | GSK3A | P49840 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | PRKX | P51817 | 3/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.45 |
| ▸ | PRKG2 | Q13237 | 3/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.45 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.45 |
| ▸ | SGK2 | Q9HBY8 | 3/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6627566 | 1.00 | TDP1 (0.45) | TDP1ROCK1ROCK2PRKG1RPS6KA5 | |
| SCHEMBL6856474 | 1.00 | TDP1 (0.45) | TDP1ROCK1ROCK2PRKG1RPS6KA5 | |
| SCHEMBL6856470 | 1.00 | TDP1 (0.45) | TDP1ROCK1ROCK2PRKG1RPS6KA5 | |
| SCHEMBL30795208 | 1.00 | TDP1 (0.45) | TDP1ROCK1ROCK2PRKG1RPS6KA5 | |
| SCHEMBL6672903 | 1.00 | TDP1 (0.45) | TDP1ROCK1ROCK2PRKG1RPS6KA5 | |
| SCHEMBL30824689 | 0.90 | TDP1 (0.44) | TDP1 | |
| SCHEMBL6670256 | 0.90 | TDP1 (0.44) | TDP1 | |
| SCHEMBL6670253 | 0.90 | TDP1 (0.44) | TDP1 | |
| SCHEMBL6670254 | 0.90 | TDP1 (0.44) | TDP1 | |
| SCHEMBL6671799 | 0.88 | TDP1 (0.44) | TDP1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831080-B2 | E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-14 | — | — | US | claimed |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | claimed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-6831080-B2 | E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-14 | — | — | US | disclosed |
| EP-1392644-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
| WO-2002096858-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | KCNH2, KCNH3, KCNQ1 | TDP1 4537/4885ROCK1 4213/4885ROCK2 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.